Chikungunya Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunities

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Projected Growth of the Chikungunya Market?
In recent times, there has been robust growth in the chikungunya market size. It is projected to expand from $0.59 billion in 2024 to $0.65 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%. Factors that have contributed to this growth during the historic period include a rise in per capita spending on healthcare, an increase in the occurrence of emerging and re-emerging infectious diseases, growth in personal disposable income, changing climate conditions, and heightened awareness about mosquito-borne diseases.

Within the forthcoming years, the chikungunya market is projected to witness a robust expansion, anticipated to reach $0.93 billion by 2029 with a compound annual growth rate (CAGR) of 9.4%. The predicted growth in the foreseeable future is due to an increase in global clinical trials, an aging population, the escalating need for vaccination, rising initiatives by the government and non-governmental organizations, growing government investments, and favorable legislations. Key trends to look forward to in the forecasted period comprise progress in biotechnological approaches for the advancement of vaccines, the emergence of new vaccine prospects, the application of CRISPR and AI in fostering innovative solutions, strategic alliances among pharmaceutical entities, and the incorporation of telemedicine services.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21137

What Are the Different Chikungunya Market Segments?
The chikungunya market covered in this report is segmented -

1) By Type: Antiviral Drugs, Herbal And Complementary Treatments, Supportive Care, Vaccines
2) By Product Form: Liquid Form, Powder, Solid Form
3) By Disease Stage: Acute, Chronic, Post-Infection
4) By Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets
5) By End User: Caregivers, Healthcare Professionals, Patients

Subsegments:
1) By Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors
2) By Herbal And Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine
3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy
4) By Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21137&type=smp

What Are the Primary Drivers Shaping the Chikungunya Market?
The escalation in instances of diseases carried by mosquitos is projected to spur the expansion of the chikungunya market. Diseases, such as chikungunya, dengue and zika virus, are passed on to humans via contaminated aedes mosquitoes, creating substantial public health issues across the globe. The increasing worldwide cases of diseases carried by mosquitos stem from factors such as climate change, urban growth, deforestation, accumulation of stagnant water, insufficient vector control procedures, heightened global travel, and resistance to insecticides. Treatments for chikungunya help those suffering from mosquito-borne diseases by alleviating symptoms like fever, joint pain, and inflammation, thus enhancing comfort and mobility, diminishing the danger of complications, and aiding recovery through hydration, pain control and supportive care. For example, the UK Health Security Agency, a government agency in the UK, reported in December 2024 that the number of dengue cases among vacationing travelers returning to England, Wales, and Northern Ireland climbed to 473 in the timeframe January to June 2024, a 201% jump as compared to the 157 cases noted during that same timeframe in 2023. Hence, the escalating global cases of diseases carried by mosquitos is fuelling the expansion of the chikungunya market.

Which Companies Are Leading in the Chikungunya Market?
Major companies operating in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.

What Trends Are Expected to Dominate the Chikungunya Market in the Next 5 Years?
Leading firms in the chikungunya market are prioritizing the creation of cutting-edge vaccines designed to boost immunity, mitigate disease outbreak, and manage the rising global health implications of chikungunya virus infections. One such vaccine is a live attenuated chikungunya vaccine. This vaccine uses a debilitated form of the chikungunya virus to provoke an immune response without inflicting the disease, creating long-lasting safeguarding. For example, in November 2023, Valneva SE, a biotechnology organization based in France, released IXCHIQ, a live attenuated chikungunya vaccine approved by the FDA, a US government agency. This approval was fast-tracked based on anti-CHIKV neutralizing antibody titers, with ongoing approval relying on the verification of clinical benefits in subsequent studies. The FDA gave Valneva a Priority Review Voucher (PRV), which the corporation plans to convert into funding for its research and development endeavors. IXCHIQ is administered in a one-time muscle injection and includes a weak, live version of the chikungunya virus, which could potentially elicit symptoms in patients similar to those caused by the chikungunya disease.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

What Are the Top Revenue-Generating Geographies in the Chikungunya Market?
North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chikungunya Market?
2. What is the CAGR expected in the Chikungunya Market?
3. What Are the Key Innovations Transforming the Chikungunya Industry?
4. Which Region Is Leading the Chikungunya Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.